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The World Health Organization (WHO) published 2 alco-
hol-based formulations to be used in healthcare settings and 
for outbreak-associated infections, but inactivation efficacies of 
these products have not been determined against (re-)emerging 
viruses. In this study, we evaluated the virucidal activity of these 
WHO products in a comparative analysis. Zika virus (ZIKV), 
Ebola virus (EBOV), severe acute respiratory syndrome coro-
navirus (SARS-CoV), and Middle East respiratory syndrome 
coronavirus (MERS-CoV) as (re-)emerging viral pathogens and 
other enveloped viruses could be efficiently inactivated by both 
WHO formulations, implicating their use in healthcare systems 
and viral outbreak situations.
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Hygienic hand antisepsis is one of the most important measures 
in preventing healthcare- and outbreak-associated viral infec-
tions. To reduce the spread of infections, biocides with a proven 
virucidal efficacy should be readily available. The World Health 
Organization (WHO) proposed in its 2009 Guidelines on Hand 
Hygiene in Health Care the use of of 2 alcohol-based hand rubs 
(formulation I and formulation II) for surgical and hygiene hand 
disinfection in healthcare settings and to reduce the transmis-
sion of pathogens by hands [1]. However, limited data exist on 
the efficacy of disinfectants, including the WHO formulations, 
against novel viruses that have emerged during recent outbreaks 
in different parts of the world. Most recently, Zika virus (ZIKV), 
a flavivirus that was discovered originally in Africa, has raised 
considerable international concern. In 2013, the largest and 
most complex outbreak of Ebola virus (EBOV), a filovirus that 
spreads mainly through contact with body fluids of symptomatic 
patients or contaminated surfaces, occurred in West Africa [2]. 
One year previously in 2012, a novel Coronavirus (CoV) named 
Middle East respiratory syndrome (MERS) emerged, preceded 
by severe acute respiratory syndrome (SARS) in 2002/2003, with 
both viruses causing acute respiratory diseases in humans and 
displaying a high case-fatality rate.
We previously evaluated the WHO formulations in a quan-
titative suspension test for chemical disinfectants and antisep-
tics in human medicine using different nonenveloped model 
viruses and observed that formulation I demonstrated a better 
activity than formulation II against these nonenveloped viruses 
[3]. However, at that time neither formulation met the require-
ments for virucidal activity against poliovirus according to the 
European Guideline (EN14476) [3] or for surgical hand treat-
ment according to the European Norm (EN12971) [4]. Since 
then, both WHO formulations have been modified with higher 
alcohol content and lower glycerol concentration and are now 
fulfilling the guideline requirements [5, 6].
In this study, we evaluated for the first time the modified 
WHO-recommended alcohol-based formulations against dif-
ferent enveloped viruses, including emerging ZIKV, EBOV, 
SARS-CoV, and MERS-CoV and performed a comparative 
inactivation analysis of these emerging viruses and other 
important reference viruses.
MATERIAL AND METHODS
Cell Culture and Viral Strains
An overview of the viruses and cell culture systems used in 
this study is given in Supplementary Table 1. Hepatitis C 
virus (HCV) chimeric Jc1 virus was generated in the human 
hepatoma cell line (Huh7.5) as previously described [7]. The 
African lineage ZIKV strain (MP1751), isolated in Uganda in 
1962, was propagated by using Vero-B4 cells like MERS-CoV 
strain EMC and SARS-CoV strain Frankfurt 1. Bovine CoV 
(BcoV) was produced in the human glioblastoma astrocytoma 
cells U373, human influenza A virus (H1N1) was produced 
in Madin-Darby canine kidney epithelial cells (MDCK) and 
modified vaccinia Ankara strain (MVA) was produced in baby 
hamster kidney cells (BHK-21). Ebola virus was propagated 
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in Vero E6 cells as previously described [8]. Ebola virus–like 
particles encoding a luciferase were generated using 239T cells 
as previously reported [9]. In general, cell lines were cultured 
in Dulbecco’s modiﬁed minimal essential medium or Eagle’s 
minimum essential medium supplemented with 10% fetal calf 
serum and other additions (Supplementary Table 1).
Quantitative Suspension Test and Virus Titrations
One part by volume of the test virus suspension and 1 part by 
volume of the organic load were mixed with 8 parts by volume 
of 1 of the 2 WHO formulations at different concentrations. 
Additional information is provided in the Supplementary 
Data.
Statistical Analyses
Concentrations at which the formulations reached the half 
maximal virus inactivation effective concentration (EC50) were 
determined using nonlinear regression using the robust fitting 
method on the normalized 50% tissue culture infectious dose 
(TCID50) data implemented in GraphPad Prism version 6.07 
for Windows. The mean TCID50 of 2 individual experiments 
and standard deviations of means were also calculated using 
GraphPad Prism. Significance of differences in mean EC50 
obtained for the viruses between WHO formulations I and II 
was tested using 2-tailed Wilcoxon matched-pairs signed rank 
test (P < .01).
RESULTS
Virucidal Activity of World Health Organization Formulations Against 
Hepatitis C Virus and Zika Virus
Hepatitis C virus and ZIKV both belong to the family of 
Flaviviridae (Supplementary Table  1) but are transmitted 
in the environment by different routes. Whereas HCV is a 
blood-borne virus [10], transmission of ZIKV occurs mainly 
through mosquitos, with the most important and com-
mon vectors being the Aedes genus. However, other modes 
of transmission, including sexual transmission, have been 
reported. To determine the efficacy of WHO formulations 
I and II against HCV and ZIKV, we incubated the 2 viruses 
for 30 seconds with the formulations at final concentrations 
ranging from 10% to 80% (Figure 1). In the case of HCV, viral 
titers started to decline at a concentration of 30% with WHO 
formulation II and 40% with WHO formulation I and were 
reduced to background levels at a concentration of 60% with 
WHO formulation I and at 40% with WHO formulation II, 
respectively (Figure 1A). As depicted in Figure 1B, a dose-de-
pendent reduction of viral titers was also observed for ZIKV 
(Figure 1B). Importantly, viral titers of 106 TCID50/mL in the 
control decreased to undetectable levels with WHO formula-
tion I at a concentration of 40%, whereas a concentration of 
only 30% was required for complete inactivation with WHO 
forumulation II.
Susceptibility of Bovine Coronoavirus, Middle East Respiratory Syndrom 
Coronavirus, and Severe Acute Respiratory Syndrome Coronoavirus to 
World Health Organization Formulations
Next, we investigated the susceptibility of emerging respiratory 
CoVs against the WHO formulations in the same experimen-
tal suspension assay setup. As reference for CoVs, which can 
be cultivated under lower biosafety levels, we included BCoV 
that naturally infects cattle. As depicted in Supplementary 
Figure 1A, WHO formulation II at a 30% concentration was 
sufficient to completely inactivate BCoV, whereas for WHO 
formulation I higher concentrations of at least 40% were 
required (Supplementary Figure 1A). Similar inactivation pro-
files could be observed for MERS-CoV (Figure 1C) and SARS-
CoV (Figure 1D), demonstrating a high susceptibility of these 
emerging CoVs to WHO formulations. Furthermore, these 
results implicate BCoV as a valid surrogate virus for inactiva-
tion studies with MERS-CoV and SARS-CoV.
Virucidal Activity of World Health Organization Formulations Against Ebola 
Virus, Human Influenza A Virus, and Modified Vaccinia Ankara Strain
Work with infectious EBOV is restricted to biosafety level 4 
laboratories, significantly limiting studies with these viruses. 
In 2014, Watt et  al reported a novel life cycle modelling 
approach for EBOV, which can be performed at biosafety 
level 2 laboratories [9]. Inactivation of these transcription- 
and replication-competent virus-like particles (trVLPs) with 
WHO formulations showed a dose-dependent reduction of 
trVLP reporter activity with increasing WHO formulation 
I and II concentrations (Figure 2A). Next, we tested full infec-
tious EBOV cultured at biosafety level 4 for its susceptibility 
to WHO formulations for potential usage in outbreak situa-
tions. Interestingly, viral titers of 107 TCID50/mL in the control 
were reduced to background levels at concentrations of 40% 
with WHO formulation II and 60% with WHO formulation 
I, showing again a superior virucidal activity of WHO formu-
lation II compared with WHO formulation I (Figure 2B). We 
also included the influenza A  virus H1N1 in these inactiva-
tion experiments because of its importance in causing viral 
respiratory epidemics and pandemics. H1N1 could be inacti-
vated at concentrations of 60% with WHO formulation I and 
40% with WHO formulation II (Supplementary Figure  1B). 
Furthermore, MVA was studied for its susceptibility to WHO 
formulations because it is the chosen test virus for all envel-
oped viruses in the European Guideline. In line with EBOV 
and H1N1, similar inactivation profiles could be observed 
with increasing WHO formulation I  and II concentrations 
(Supplementary Figure 1C).
Comparative Inactivation Profiles for World Health Organization 
Formulations Against Enveloped Viruses
Based on the obtained virucidal activities of the WHO for-
mulations against the different enveloped viruses, we next 
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analyzed the inactivation profiles in a comparative analysis 
(Figure 2C and 2D). The most susceptible viruses to the WHO 
formulation I were the bovine and emerging CoVs (BCoV, 
SARS-CoV, MERS-CoV) and ZIKV (Figure 2C). With a shift 
to increasing WHO forumation I concentration, the more 
stable viruses included the full infectious EBOV (trVLPs 
excluded in this analysis) and HCV (Figure 2C). The highest 
alcohol-based concentrations of WHO formulation I (>40%) 
were required for H1N1 and MVA, which displayed nearly 
identical inactivation response curves (Figure 2C). The results 
for the isopropanol-based WHO formulation II are depicted 
in Figure 2D; it demonstrated a similar pattern of suscepti-
bility for the different enveloped viruses with an obvious shift 
toward lower concentrations (Figure 2D). The CoVs and ZIKV 
showed the highest susceptibility to WHO formulation II, 
whereas HCV, EBOV, H1N1 and MVA demonstrated a more 
resistant inactivation profile (Figure 2D). To also directly com-
pare the performance of the 2 WHO formulations, we deter-
mined the concentrations at which the products reached the 
EC50 (Supplementary Figure 2). World Health Organization 
formulation II showed a significantly higher virucidal activity 
against the different viruses compared with WHO formulation 
I (P = .008). In summary, CoVs and ZIKV showed the high-
est susceptibility to WHO formulations. Ebola virus and HCV 
were observed to be less susceptible than the CoVs, whereas 
H1N1 and MVA were the most stable viruses. In addition, 
WHO formulation II demonstrated a higher virucidal effect 
compared with WHO formulation I.
Figure 1. Virucidal activity of World Health Organization (WHO) formulations I and II against hepatitis C virus (HCV), Zika virus (ZIKV), Middle East respiratory syndrome 
coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). A, World Health Organization formulations I and II were tested for their efficacy in 
inactivating HCV. The biocide concentrations ranged from 0% to 80% with an exposure time of 30 seconds. For this inactivation assay, 1 part virus and 1 part organic load 
were mixed with 8 parts biocide. Residual infectivity was determined by a limiting dilution assay. Viral titers are displayed as 50% tissue culture infectious dose (TCID50) 
values. The cytotoxicity was calculated in analogy to the determination of virus titer (TCID50/mL) and is depicted as a dashed line. The means of 2 independent experiments 
with standard deviations are shown. Efficacy of WHO formulations I and II against ZIKV (B), MERS-CoV (C), and SARS-CoV (D) was addressed by a quantitative suspension 
assay as described for panel A. Abbreviation: nd, not detected.
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DISCUSSION
The WHO has recommended 2 formulations in Guidelines on 
Hand Hygiene in Health Care, a document proposing the use 
of cheap alcohol-based hand rubs to reduce the transmission of 
pathogens [1]. We aimed in this study to analyze the virucidal 
efficacies of these products, particularly against emerging or 
re-emerging viruses that caused severe epidemics in the recent 
past [2]. Importantly, both WHO formulations inactivated all 
tested viruses, including ZIKV, EBOV, and emerging CoVs, in a 
suspension test with 30-second exposure time, implicating the 
Figure 2. Effect of World Health Organization formulations I and II against Ebola virus (EBOV) and comparative viral susceptibility analysis. World Health Organization 
formulations I and II were tested for their efficacy in inactivating EBOV transcription- and replication-competent virus-like particles (trVLPs) (A) and EBOV (B). The biocide con-
centrations ranged from 0% to 80% with an exposure time of 30 seconds. For this inactivation assay, 1 part virus and 1 part organic load were mixed with 8 parts of biocide. 
For determination of the EBOV trVLP infectivity, luciferase activity was measured 72 hours later. For EBOV, residual infectivity was determined by a limiting dilution assay. 
Viral titers are displayed as 50% tissue culture infectious dose (TCID50) values. The cytotoxicity was calculated in analogy to the determination of virus titer (TCID50/mL) and is 
depicted as a dashed line. The means of 2 independent experiments with standard deviations are shown. Normalized values of percentage inactivation of viral infectivity (y-axis) 
were plotted against WHO formulations I (C) or II (D) in dose-response curves (x-axis, log representation). Viruses are listed in each panel and are ranked from the most to the 
least stable. Normalization and nonlinear regression calculation of all data were performed using GraphPad Prism version 6.07 for Windows. Abbreviation: nd, not detected.
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usability of these formulations in viral outbreak situations. In 
the case of ZIKV, specific viral inactivation data are lacking, and 
consequently disinfection guidelines are based on data obtained 
from other members of the flaviviruses. So far, 1 recent study 
by Müller et al reported that ZIKV was inactivated by classical 
inactivation methods including ultraviolet light [11]. Zika virus 
was readily reduced in viral titers by the WHO formulations, 
similar to the other member of the family of Flaviviridae, HCV. 
These findings are supported by earlier analyses of the environ-
mental stability and inactivation profiles of HCV, which showed 
strong virucidal effects of the main WHO formulation ingre-
dients ethanol and isopropanol [12]. For EBOV, limited data 
on the efficacy of virucidal products are available because these 
viruses require high biosafety level laboratories. The Centers 
for Disease Control and Prevention advises “suitable disinfec-
tant solutions include 0.5% sodium hypochloride as well as 2% 
glutaraldehyde and phenolic disinfectants (0.5–3%)” for EBOV 
inactivation [13]. The comparative inactivation analyses of all 
viruses tested revealed that the CoVs, in particular SARS-CoV, 
were the most susceptible viruses to WHO formulation treat-
ment. The degree of susceptibility of the different viruses to the 
WHO formulation likely depends on the specific surface prop-
erties of the lipophilic envelope of the respective virus. We could 
show by a comparative inactivation analysis that H1N1 and 
MVA showed the highest stability against alcohol-based inacti-
vation, with higher concentrations of WHO formulation I and 
II being required compared with CoVs, ZIKV, and EBOV. These 
results confirm MVA as the model surrogate virus for all envel-
oped viruses for testing chemical disinfectants and antiseptics 
in human medicine [8]. When testing nonenveloped viruses 
like noro-, polio-, or adenovirus, a far higher level of resistance 
to both WHO formulations was observed, probably due to the 
more hydrophilic character of these viruses [3, 6]. Interestingly, 
WHO formulation I was superior compared with WHO formu-
lation II in inactivating these nonenveloped viruses, whereas in 
this study the opposite effect occurred, with WHO formulation 
II showing a higher virucidal activity against enveloped viruses. 
This discrepancy can be explained by the presence of the virus 
envelope, which likely renders enveloped viruses more suscep-
tible to the isopropanol-based WHO formulation II compared 
with the ethanol-based WHO formulation I [14]. Furthermore, 
isopropanol has 1 more carbon than ethanol, giving it greater 
lipophilic properties and higher virucidal activities against lipo-
philic viruses [15].
In conclusion, WHO-recommended alcohol-based formula-
tions were validated with different enveloped viruses. A strong 
virucidal effect against emerging pathogens, including ZIKV, 
EBOV, SARS-CoV, and MERS-CoV, could be demonstrated, 
implicating the usability of these WHO formulations in health-
care and outbreak-associated viral infections.
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